RxDoctor Payments DataLook up a doctor →

Joseph Padalino, MD

Urology · Tulsa, OKNPI 1730322744

Payments from drug & device makers

$8,573in general payments, 2019–2025

Across 318 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calyxo, Inc.$1K
  • Johnson & Johnson$974
  • Urogen Pharma, Inc.$769
  • Astellas Pharma US Inc$674
  • Dendreon Pharmaceuticals LLC$410
  • Pfizer$395
  • plus $4K from 40 others

What the payments were for

  • Travel & lodging$7198%
  • Food & beverage$7,69390%
  • Education$1612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,573 in reported general payments places this provider in the 70th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$287,760
Medicare patients
1,258
Services billed
22,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron83$82,518
Abiraterone Acetate24$63,658
MyrbetriqMirabegron48$34,679
Tamsulosin Hcl534$6,170
Finasteride314$3,601
Trospium Chloride ErTrospium Chloride18$2,039
Estradiol31$2,023
Solifenacin Succinate35$1,338
Testosterone Cypionate27$1,068
Oxybutynin Chloride64$987
Potassium Citrate ErPotassium Citrate13$954
Alfuzosin Hcl ErAlfuzosin Hcl26$648
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$350
NitrofurantoinNitrofurantoin Macrocrystal12$294
Oxybutynin Chloride ErOxybutynin Chloride26$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$266$82,51883 claims
Astellas Pharma US IncMyrbetriq$674$34,67948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 145 urology providers in Oklahoma.

Other urology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →